Metaphorics, Syrrx Ink Ligand-Docking Partnership | GenomeWeb

NEW YORK, March 1 - Bioinformatics company Metaphorics has struck a  research collaboration with drug-discovery firm Syrrx designed to improve computational tools for docking ligand molecule structures into protein binding sites.

The companies said on Thursday that the collaboration seeks to create new software that might help scientists better predict "the potential complementarity" between ligands and proteins.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.

Research funding in Canada is to remain mostly the same, ScienceInsider reports.

In Science this week: random DNA replication errors play role in cancer, and more.

The Bill and Melinda Gates Foundation embarks on an open-access publishing path.